Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology Pub Date : 2026-01-01 Epub Date: 2025-12-11 DOI:10.1016/j.oraloncology.2025.107818

A. Hafström , E. Hammerlid , M. Beran , M. Olin , A. Högmo , L. Farnebo

{"title":"Treatment and outcome for 2,111 patients with vermilion lip squamous cell carcinoma: A nationwide, population-based study from the SweHNCR","authors":"A. Hafström , E. Hammerlid , M. Beran , M. Olin , A. Högmo , L. Farnebo","doi":"10.1016/j.oraloncology.2025.107818","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and importance</h3><div>The major risk factor for vermilion lip squamous cell carcinoma (vlSCC) is excessive sunlight exposure. Population-based studies on treatment and outcome are lacking.</div></div><div><h3>Methods</h3><div>This is a nation-wide, population-based study of treatment and outcome from prospectively recorded data for 2,111 vlSCC registered in the Swedish Head and Neck Cancer Register (SweHNCR) diagnosed 2008–2022.</div></div><div><h3>Results</h3><div>The age standardized incidence increased with 34 % between 2008 and 2022, from 1.14 to 1.53 per 100,000 (19 % for males and 55 % for females). Median age at diagnosis was 76 years and 72.4 % had good performance status. Males predominated (57.1 %). Lower lip vlSCC comprised 82.6 % and upper 8.6 %. Most had T1 (81.7 %) or T2 (13.5 %) tumors and few had regional (2.7 %) or distant (0.1 %) metastases. The 5-year observed overall survival was 70.5 % (95 % CI 68.4–72.6) and relative survival 90.8 % (95 % CI 88.2–93.7).</div><div>Treatment data were registered in 1,948 cases and 97.5 % (1,900) had a curative intent, whereof 88.5 % had surgery, 7.3 % radiotherapy, and 4.2 % combination treatment. Recurrences were registered in 5.6 % (48.6 % local, 42.1 % regional) whereof 15.9 % after three years. Stage I recurred after median 17 (IQR 9–28) months whereas stage II and III after 10 months (7–17 and 9–13, respectively). Advanced age (p < 0.001), poor performance status (p < 0.001), male sex (p = 0.002), high stage (p = 0.041), and only radiotherapy (p = 0.007) remained as independent prognostic factors for mortality.</div></div><div><h3>Conclusion</h3><div>Females had higher incidence increase than males. Advanced age, poor performance status, male sex, advanced disease, and radiotherapy only were independent prognostic factors for mortality.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"172 ","pages":"Article 107818"},"PeriodicalIF":4.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368837525006475","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background and importance

The major risk factor for vermilion lip squamous cell carcinoma (vlSCC) is excessive sunlight exposure. Population-based studies on treatment and outcome are lacking.

Methods

This is a nation-wide, population-based study of treatment and outcome from prospectively recorded data for 2,111 vlSCC registered in the Swedish Head and Neck Cancer Register (SweHNCR) diagnosed 2008–2022.

Results

The age standardized incidence increased with 34 % between 2008 and 2022, from 1.14 to 1.53 per 100,000 (19 % for males and 55 % for females). Median age at diagnosis was 76 years and 72.4 % had good performance status. Males predominated (57.1 %). Lower lip vlSCC comprised 82.6 % and upper 8.6 %. Most had T1 (81.7 %) or T2 (13.5 %) tumors and few had regional (2.7 %) or distant (0.1 %) metastases. The 5-year observed overall survival was 70.5 % (95 % CI 68.4–72.6) and relative survival 90.8 % (95 % CI 88.2–93.7).

Treatment data were registered in 1,948 cases and 97.5 % (1,900) had a curative intent, whereof 88.5 % had surgery, 7.3 % radiotherapy, and 4.2 % combination treatment. Recurrences were registered in 5.6 % (48.6 % local, 42.1 % regional) whereof 15.9 % after three years. Stage I recurred after median 17 (IQR 9–28) months whereas stage II and III after 10 months (7–17 and 9–13, respectively). Advanced age (p < 0.001), poor performance status (p < 0.001), male sex (p = 0.002), high stage (p = 0.041), and only radiotherapy (p = 0.007) remained as independent prognostic factors for mortality.

Conclusion

Females had higher incidence increase than males. Advanced age, poor performance status, male sex, advanced disease, and radiotherapy only were independent prognostic factors for mortality.

查看原文本刊更多论文

2111例红唇鳞状细胞癌患者的治疗和结果：一项来自SweHNCR的全国性、基于人群的研究

背景和重要性朱红色唇鳞状细胞癌（vlSCC）的主要危险因素是过度的阳光照射。目前缺乏以人群为基础的治疗和结果研究。方法：这是一项全国性的、基于人群的研究，对2008-2022年在瑞典头颈癌登记处（SweHNCR）诊断的2111例vlSCC的治疗和结果进行前瞻性记录。结果2008年至2022年，年龄标准化发病率从1.14 / 10万增加到1.53 / 10万，增加了34%（男性19%，女性55%）。诊断时的中位年龄为76岁，72.4%的患者表现良好。男性占多数（57.1%）。下唇vlSCC占82.6%，上唇占8.6%。大多数为T1（81.7%）或T2（13.5%）肿瘤，少数为局部（2.7%）或远处（0.1%）转移。5年观察总生存率为70.5% (95% CI 68.4-72.6)，相对生存率为90.8% （95% CI 88.2-93.7）。登记的治疗资料为1948例，97.5%（1900例）有治愈意图，其中手术治疗占88.5%，放疗占7.3%，联合治疗占4.2%。复发率为5.6%（本地48.6%，区域42.1%），三年后复发率为15.9%。I期复发的中位时间为17个月（IQR为9-28），II期和III期复发的中位时间为10个月（分别为7-17和9-13）。高龄（p < 0.001）、表现不佳（p < 0.001）、男性（p = 0.002）、晚期（p = 0.041）和仅放疗（p = 0.007）仍然是死亡的独立预后因素。结论女性发病率高于男性。高龄、运动状态差、男性、疾病晚期和放疗仅是死亡率的独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral oncology 医学-牙科与口腔外科

CiteScore

8.70

自引率

10.40%

发文量

505

审稿时长

20 days

期刊介绍： Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck. Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.